Boston Tech
Mass General Got $25.8 Million to Send Gene Editors Into Blood Vessels
Mass General won up to $25.8 million from ARPA-H to build a reusable gene-editing platform for rare vascular diseases in Boston and beyond for patients.
Boston Tech
Prime Medicine Beat Beam in Gene-Editing Arbitration, and Cambridge Called It Family Therapy
Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.
Boston Tech
Vertex Expanded Casgevy to Age 2, and Boston's CRISPR Future Now Comes in Toddler Sizes
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.